Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

atoplab.com
 

Enter Stock Symbol:  

Blueprint Medicines Corporation (BPMC)

69.5 -2.57 (-3.57%)

10-17 10:52

Open:

71.93

Pre. Close:

72.07

High:

71.93

Low:

69.05

Volume:

79,951

Market Cap:

3050M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

72.523 - 72.867

72.867 - 73.19

Low:

67.051 - 67.433

67.433 - 67.791

Close:

71.419 - 72.042

72.042 - 72.627

Technical analysis  (as of: 2018-10-17 10:26:00 AM)

Overall:

      

Stoxline rating system posted a NEUTRAL today, downgraded from higher rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.

Target:

Six months: 87.12     One year: 93.00

Support:

Support1: 66.46    Support2: 55.29

Resistance:

Resistance1: 74.59    Resistance2: 79.62

Pivot:

71.19

Moving Averages:

MA(5): 69.13     MA(20): 71.69

MA(100): 69.98     MA(250): 76.59

MACD:

MACD(12,26): -0.97     Signal(12,26,9): -0.68

%K %D:

%K(14,3): 25.51     %D(3): 20.82

RSI:

RSI(14): 46.23

52-Week:

High: 109  Low: 57.44  Change(%): 8.0

Average Vol(K):

3-Month: 31757  10-Days 29377

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
BPMC has closed above bottom band by 36.9%. Bollinger Bands are 12.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-10-06T08:50:00-04:00
Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology

Shares Out. (M)

43.89

Shares Float (M)

43.27

% Held by Insiders

% Held by Institutions

Shares Short (K)

3020

Shares Short Prior Month (K)

Stock Financials

EPS

-4.100

EPS Est. Current Year

-3.660

EPS Est. Next Year

-4.410

EPS Est. Next Quarter

-1.050

Forward EPS

-5.671

Book Value (p.s.)

5.350

PEG Ratio

Profit Margin

Operating Margin

-339.96

Return on Assets (ttm)

-30.7

Return on Equity (ttm)

-36.8

Qtrly Rev. Growth

603.5

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.849

Qtrly Earnings Growth

Operating Cash Flow (M)

-113.69

Levered Free Cash Flow (M)

-91.96

Valuation

P/E

-16.92

P/E Growth Ratio

-0.04

P/BV

12.96

P/S

2435368192.00

P/CF

-26.78

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.